非那雄胺在BPH的临床疗效及安全性评估-浙江省湖州市第一人民医院-陈宇.pdfVIP

Clinical efficacy and safety of Finasteride for BPH 非那雄胺在前列腺增生症中的临床疗效及安全性评估 Chen Yu Department of Urology The First People ‘s Hospital of Huzhou, 浙江省湖州市第一人民医院 A . The prevalence of prostate enlargement in the general population B . The prevalence of prostate enlargemen by the age of 60 years C . The prevalence of prostate enlargemen by the age of 85 years R.S. Kirby, et al., Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial, Urology 61 (1) (2003) 119–126. Clinical efficacy A 55% risk reduction with Finasteride® （PLESS study n=3040) 4. McConnell JD, Bruskewitz R, Walsh P,et al., The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557-63. A 57% reduction in the risk for AUR with Finasteride® （PLESS study n=3040) 7% 3% 4. McConnell JD, Bruskewitz R, Walsh P,et al., The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998;338(9):557-63. ® Finasteride :decrease in American Urological